Akums AGM approves dividend, MD pay amid opposition

1 min read Updated on 11 Jul 2026, 06:52 PM

Reviewed by

Ashish TScanX News Team

AI Summary

Akums Drugs & Pharmaceuticals disclosed the voting results for its 22nd AGM held on July 10, 2026, confirming the approval of all six resolutions, including the adoption of financial statements for FY26 and dividend declaration. While ordinary resolutions passed with near-unanimous support, special resolutions regarding the remuneration of Managing Directors Mr. Sanjeev Jain and Mr. Sandeep Jain faced notable opposition, securing approximately 91.58% approval.

*this image is generated using AI for illustrative purposes only.

Akums Drugs & Pharmaceuticals announced the voting results for its 22nd Annual General Meeting held on July 10, 2026, confirming the approval of all six resolutions. Shareholders sanctioned the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and declared a dividend on equity shares for the same period. The meeting, conducted via video conferencing, was attended by 123 members, with 71,018 shareholders recorded as of the cut-off date of July 3, 2026.

Voting Outcomes

The resolutions were passed with the requisite majority, though special resolutions regarding remuneration revisions faced significant opposition. The re-appointment of Mr. Sanjay Sinha (DIN: 03627342) as Director was approved with 98.92% of votes in favour. However, the special resolutions to revise the remuneration of Managing Directors Mr. Sanjeev Jain and Mr. Sandeep Jain received 91.58% approval, with 8.42% of votes cast against them.

Resolution	Votes In Favour	Votes Against	% In Favour
Adoption of financial statements	143,583,889	48	100.00%
Dividend declaration	143,583,889	48	100.00%
Re-appointment of Mr. Sanjay Sinha	142,028,986	1,554,951	98.92%
Ratification of Cost Auditors' remuneration	143,583,746	191	99.99%
Revision of remuneration for Mr. Sanjeev Jain	131,497,345	12,086,592	91.58%
Revision of remuneration for Mr. Sandeep Jain	131,497,413	12,086,624	91.58%

Scrutinizer's Report

CS Suresh Pandey of SPG and Associates, appointed as the Scrutinizer, oversaw the remote e-voting process conducted in collaboration with National Securities Depository Limited (NSDL). Remote e-voting commenced on July 6, 2026, and concluded on July 9, 2026. The votes were unblocked on July 10, 2026, in the presence of independent witnesses. The results have been communicated to the National Stock Exchange of India Ltd. and BSE Limited.

Historical Stock Returns for Akums Drugs & Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+6.65%	+10.12%	+28.03%	+57.81%	+24.96%	-11.84%

How might the significant opposition to the remuneration revisions for the Managing Directors influence future executive compensation strategies?

What impact will the approved dividend have on Akums Drugs' cash flow and upcoming investment plans?

Could the dissent on remuneration revisions signal growing shareholder activism regarding corporate governance at Akums Drugs?

Read Next Article

Akums subsidiary penalty of INR 3.59 Cr set aside by authority

1 min read Updated on 07 Jul 2026, 12:21 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

The First Appellate Authority in Ahmedabad set aside a INR 3.59 Cr penalty on Akums Drugs & Pharmaceuticals' subsidiary, Maxcure Nutravedics. The penalty was issued due to an incorrect shipping address in October 2025 invoices. The company confirmed no financial impact from the order.

*this image is generated using AI for illustrative purposes only.

The First Appellate Authority in Ahmedabad has set aside a penalty of INR 3,59,10,000 imposed on Maxcure Nutravedics Limited, a wholly-owned subsidiary of Akums Drugs & Pharmaceuticals . The order, dated July 03, 2026, reverses the earlier decision by the Deputy Commissioner of State Tax, Gujarat, providing relief to the subsidiary regarding a tax dispute arising from invoicing errors in October 2025.

The penalty was initially levied because the shipping address was mistakenly entered incorrectly in the invoice and e-way bill for October 2025. Following an appeal, the First Appellate Authority reviewed the case and vacated the penalty, effectively removing the financial liability that had been proposed against the subsidiary.

Akums Drugs and Pharmaceuticals Limited stated that there will be no financial impact on the company as a result of this order. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Details of the Order

Particulars	Details
Name of the Authority	Deputy Commissioner of State Tax, Appeal (1), Division 1, Ahmedabad, Gujarat
Nature of Action	Orders for imposition of penalty of INR 3,59,10,000 set aside
Date of Order	July 03, 2026
Reason for Violation	Shipping address mistakenly entered incorrect in invoice and e-way bill of October 2025
Financial Impact	No financial impact on the Company